BACKGROUND: Several biomarkers have been individually associated with vascular brain injury, but no prior study has explored the simultaneous association of a biologically plausible panel of biomarkers with the incidence of stroke/transient ischemic attack and the prevalence of subclinical brain injury. METHODS AND RESULTS: In 3127 stroke-free Framingham offspring (age, 59±10 years; 54% female), we related a panel of 8 biomarkers assessing inflammation (C-reactive protein), hemostasis (D-dimer and plasminogen activator inhibitor-1), neurohormonal activity (aldosterone-to-renin ratio, B-type natriuretic peptide, and N-terminal proatrial natriuretic peptides), and endothelial function (homocysteine and urinary albumin/creatinine ratio) measured at the sixth examination (1995-1998) to risk of incident stroke/transient ischemic attack. In a subset of 1901 participants with available brain magnetic resonance imaging (1999-2005), we further related these biomarkers to total cerebral brain volume, covert brain infarcts, and large white-matter hyperintensity volume. During a median follow-up of 9.2 years, 130 participants experienced incident stroke/transient ischemic attack. In multivariable analyses adjusted for stroke risk factors, the biomarker panel was associated with incident stroke/transient ischemic attack and with total cerebral brain volume (P<0.05 for both) but not with covert brain infarcts or white-matter hyperintensity volume (P>0.05). In backward elimination analyses, higher log-B-type natriuretic peptide (hazard ratio, 1.39 per 1-SD increment; P=0.002) and log-urinary albumin/creatinine ratio (hazard ratio, 1.31 per 1-SD increment; P=0.004) were associated with increased risk of stroke/transient ischemic attack and improved risk prediction compared with the Framingham Stroke Risk Profile alone; when the <5%, 5% to 15%, or >15% 10-year risk category was used, the net reclassification index was 0.109 (P=0.037). Higher C-reactive protein (β=-0.21 per 1-SD increment; P=0.008), D-dimer (β=-0.18 per 1-SD increment; P=0.041), total homocysteine (β=-0.21 per 1-SD increment; P=0.005), and urinary albumin/creatinine ratio (β=-0.15 per 1-SD increment; P=0.042) were associated with lower total cerebral brain volume. CONCLUSION: In a middle-aged community sample, we identified multiple biomarkers that were associated with clinical and subclinical vascular brain injury and could improve risk stratification.
BACKGROUND: Several biomarkers have been individually associated with vascular brain injury, but no prior study has explored the simultaneous association of a biologically plausible panel of biomarkers with the incidence of stroke/transient ischemic attack and the prevalence of subclinical brain injury. METHODS AND RESULTS: In 3127 stroke-free Framingham offspring (age, 59±10 years; 54% female), we related a panel of 8 biomarkers assessing inflammation (C-reactive protein), hemostasis (D-dimer and plasminogen activator inhibitor-1), neurohormonal activity (aldosterone-to-renin ratio, B-type natriuretic peptide, and N-terminal proatrial natriuretic peptides), and endothelial function (homocysteine and urinary albumin/creatinine ratio) measured at the sixth examination (1995-1998) to risk of incident stroke/transient ischemic attack. In a subset of 1901 participants with available brain magnetic resonance imaging (1999-2005), we further related these biomarkers to total cerebral brain volume, covert brain infarcts, and large white-matter hyperintensity volume. During a median follow-up of 9.2 years, 130 participants experienced incident stroke/transient ischemic attack. In multivariable analyses adjusted for stroke risk factors, the biomarker panel was associated with incident stroke/transient ischemic attack and with total cerebral brain volume (P<0.05 for both) but not with covert brain infarcts or white-matter hyperintensity volume (P>0.05). In backward elimination analyses, higher log-B-type natriuretic peptide (hazard ratio, 1.39 per 1-SD increment; P=0.002) and log-urinary albumin/creatinine ratio (hazard ratio, 1.31 per 1-SD increment; P=0.004) were associated with increased risk of stroke/transient ischemic attack and improved risk prediction compared with the Framingham Stroke Risk Profile alone; when the <5%, 5% to 15%, or >15% 10-year risk category was used, the net reclassification index was 0.109 (P=0.037). Higher C-reactive protein (β=-0.21 per 1-SD increment; P=0.008), D-dimer (β=-0.18 per 1-SD increment; P=0.041), total homocysteine (β=-0.21 per 1-SD increment; P=0.005), and urinary albumin/creatinine ratio (β=-0.15 per 1-SD increment; P=0.042) were associated with lower total cerebral brain volume. CONCLUSION: In a middle-aged community sample, we identified multiple biomarkers that were associated with clinical and subclinical vascular brain injury and could improve risk stratification.
Authors: James R Madison; Christian Spies; Irwin J Schatz; Kamal Masaki; Randi Chen; Katsuhiko Yano; J David Curb Journal: Arch Intern Med Date: 2006-04-24
Authors: Johan Arnlöv; Jane C Evans; James B Meigs; Thomas J Wang; Caroline S Fox; Daniel Levy; Emelia J Benjamin; Ralph B D'Agostino; Ramachandran S Vasan Journal: Circulation Date: 2005-08-08 Impact factor: 29.690
Authors: Charles DeCarli; Joseph Massaro; Danielle Harvey; John Hald; Mats Tullberg; Rhoda Au; Alexa Beiser; Ralph D'Agostino; Philip A Wolf Journal: Neurobiol Aging Date: 2005-04 Impact factor: 4.673
Authors: R N Bryan; S W Wells; T J Miller; A D Elster; C A Jungreis; V C Poirier; B K Lind; T A Manolio Journal: Radiology Date: 1997-01 Impact factor: 11.105
Authors: A G Bostom; I H Rosenberg; H Silbershatz; P F Jacques; J Selhub; R B D'Agostino; P W Wilson; P A Wolf Journal: Ann Intern Med Date: 1999-09-07 Impact factor: 25.391
Authors: Rohit R Das; Sudha Seshadri; Alexa S Beiser; Margaret Kelly-Hayes; Rhoda Au; Jayandra J Himali; Carlos S Kase; Emelia J Benjamin; Joseph F Polak; Christopher J O'Donnell; Mitsuhiro Yoshita; Ralph B D'Agostino; Charles DeCarli; Philip A Wolf Journal: Stroke Date: 2008-06-26 Impact factor: 7.914
Authors: Carole Dufouil; Alexa Beiser; Leslie A McLure; Philip A Wolf; Christophe Tzourio; Virginia J Howard; Andrew J Westwood; Jayandra J Himali; Lisa Sullivan; Hugo J Aparicio; Margaret Kelly-Hayes; Karen Ritchie; Carlos S Kase; Aleksandra Pikula; Jose R Romero; Ralph B D'Agostino; Cécilia Samieri; Ramachandran S Vasan; Genevieve Chêne; George Howard; Sudha Seshadri Journal: Circulation Date: 2017-02-03 Impact factor: 29.690
Authors: Natalia S Rost; Lisa Cloonan; Allison S Kanakis; Kaitlin M Fitzpatrick; Danielle R Azzariti; Virginia Clarke; Charles M Lourenco; Dominique P Germain; Juan M Politei; György A Homola; Claudia Sommer; Nurcan Üçeyler; Katherine B Sims Journal: Neurology Date: 2016-04-20 Impact factor: 9.910
Authors: Yashashwi Pokharel; Farah Mouhanna; Andrea L C Schneider; Andreea M Rawlings; David S Knopman; Vijay Nambi; Salim S Virani; Ron C Hoogeveen; Alvaro Alonso; Gerardo Heiss; Josef Coresh; Thomas Mosley; Rebecca Gottesman; Elizabeth Selvin; Christie Ballantyne; Melinda C Power Journal: J Am Geriatr Soc Date: 2019-07-30 Impact factor: 5.562
Authors: Ashkan Shoamanesh; Sarah R Preis; Alexa S Beiser; Ramachandran S Vasan; Emelia J Benjamin; Carlos S Kase; Philip A Wolf; Charles DeCarli; Jose R Romero; Sudha Seshadri Journal: Neurology Date: 2015-01-28 Impact factor: 9.910
Authors: A Vilar-Bergua; I Riba-Llena; C Nafría; A Bustamante; V Llombart; P Delgado; J Montaner Journal: J Cereb Blood Flow Metab Date: 2016-01 Impact factor: 6.200
Authors: Charlotte Andersson; Sarah R Preis; Alexa Beiser; Charles DeCarli; Kai C Wollert; Thomas J Wang; James L Januzzi; Ramachandran S Vasan; Sudha Seshadri Journal: Stroke Date: 2015-07-28 Impact factor: 7.914